Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

707

Shown on this page

Local recruiting

141

Local phase groups

The trial list below is retrieved from the live ClinicalTrials.gov search API for Multiple Myeloma. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 707 matching trials for Multiple Myeloma.

Indexed local directory records.

Phase distribution

Phase 2 335

Phase 1 260

Phase 3 64

Not applicable 56

Early Phase 1 8

Phase 4 7

Top locations

New York, New York 218 Boston, Massachusetts 171 Atlanta, Georgia 118 Houston, Texas 111 Nashville, Tennessee 90 St Louis, Missouri 88

Top sponsors

Janssen Research & Development, LLC 31 Memorial Sloan Kettering Cancer Center 30 Celgene 24 National Cancer Institute (NCI) 23 Massachusetts General Hospital 20 University of Arkansas 19

Top therapies

Dexamethasone 148 Lenalidomide 84 Bortezomib 65 Daratumumab 54 Pomalidomide 51 Carfilzomib 45

Indexed official records

Open in full search

Conditions: Multiple Myeloma
Interventions: ABBV-438; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 2 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Dexamethasone, Etentamig, Lenalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Multiple Myeloma
Interventions: Etentamig (ABBV-383); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 21 more

Conditions: Hematological Malignancy, Leukemia, Lymphoid Leukemia, Monocytic Leukemia, Multiple Myeloma, Myeloid Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
Interventions: Behavioral Coaching Intervention, Virtual Exercise Platform; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: Cancer Therapeutic Procedure, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer, Lung Cancer, Melanoma, Multiple Myeloma, Prostate Cancer
Interventions: mHealth Intervention; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma, Secondary Immunodeficiency
Interventions: IGI, 10%; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Bortezomib, Carfilzomib, Dexamethasone, Pomalidomide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Torrance, California • Fort Myers, Florida • Macon, Georgia + 3 more

Conditions: Advanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions: Abemaciclib, Atezolizumab and Talazoparib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD), Futibatinib, Nivolumab and Ipilimumab, Olaparib, Palbociclib, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib; Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Iberdomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Etentamig, Pomalidomide, Selinexor; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Elranatamab, Pomalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 97
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

About this Multiple Myeloma clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Multiple Myeloma clinical trials

Filter and sort this condition

Phase distribution

Top locations

Top sponsors

Top therapies

Indexed official records

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Halt Aging in Survivors of Blood Cancers

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

About this Multiple Myeloma clinical trials directory page